Ibandronate sodium monohydrate (BM-21.0955, Bondronat)is a potent bisphosphonate drug and bone resorption inhibitor for the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in the people with cancer. It has been investigated for in vitro anti-tumor effects, such as apoptosis induction, inhibitor of cell growth, inhibition of invasive behavior, and inhibition of angiogenesis and for its in vivo role in various cancers including breast and prostate cancers.
BM 21.0955, a potent new bisphosphonate to inhibit bone resorption.
Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy.
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians.
Breast cancer bone metastases: pathogenesis and therapeutic targets.
 R.C.Muhlbauer, et al, J. Bone Miner. Res., 1991, 6(9), pp 1003-1011.
 M.Pecherstorfer, et al, J. Clin. Oncol., 1996, 14(1), pp 268-276.
 A.Qaseem, et al, Ann. Intern. Med., 2017, 166(11), pp 818-839.
 N.Brook, et al, Int. J. Biochem. Cell Biol., 2018, 96, pp 63-78.